Liu, L., Li, S., Liu, Z., Liu, Y., Li, K., Cong, L., Cao, F., Liu, A., Liu, H., Li, L., Qu, L., Zhai, Y., Wang, F., Zhou, D., Wang, P., Li, J., Shi, D. (2026). Disitamab vedotin (RC48), tislelizumab, and S-1 as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Updated survival and exploratory biomarker results from the RCTS trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4065